Status and phase
Conditions
Treatments
About
This phase IIa trial studies long-term low-dose erlotinib hydrochloride treatment to assess its efficacy and safety to prevent development of hepatocellular carcinoma in patients with liver cirrhosis.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
30 participants in 1 patient group
Loading...
Central trial contact
Amit Singal, MD, MS; Yujin Hoshida, MD, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal